Arrowhead Pharmaceuticals, Inc. today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being ...
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback